Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 13/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 10/20 | 0.71 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.71 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.67 |
| ▸ | CHUK | O15111 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | MYLK | Q15746 | 1/20 | 0.67 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.67 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812719 | 0.92 | TMPRSS4 (0.85) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330128 | 0.91 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL18341120 | 0.91 | TMPRSS4 (0.83) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330282 | 0.91 | TMPRSS4 (0.83) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL23303643 | 0.90 | TMPRSS4 (0.81) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330225 | 0.88 | TMPRSS4 (0.79) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL13189549 | 0.88 | TMPRSS4 (0.79) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL14886085 | 0.88 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL14886006 | 0.85 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL14885880 | 0.85 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| CN-114159416-B | Novel application of small molecule inhibitor | 南方科技大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-114159416-A | Novel application of small molecule inhibitor | 南方科技大学 | 2022-03-11 | — | — | CN | disclosed |
| US-9266872-B2 | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-02-23 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| WO-2013058613-A2 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국생명공학연구원 (KR) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | TMPRSS4 2/4885P2RX1 4273/4885P2RX4 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.